Table 3 Multivariable Cox Proportional Hazard Regression Analysis for SMNs and SNMNs.

Variable	Number of survivors	SMN^a			SNMN^b
Variable	Number of survivors	Number of SMN	HR	95% CI	Number of SNMN	HR	95% CI
Sex
Male	1672	45	1 (ref)		93	1 (ref)
Female	1357	41	1.1	0.7-1.8	122	1.7	1.3-2.3
Age at diagnosis (years)
0–4	1249	31	1 (ref)		83	1 (ref)
5–9	1210	31	0.7	0.4-1.2	90	0.8	0.7-1.2
10–14	442	18	0.9	0.5-1.7	36	0.4	0.5-1.0
14+	128	6	1.4	0.6-3.8	6	0.2	0.2-1.1
Cranial radiotherapy
No	2356	38	1 (ref)		105	1 (ref)
Yes	446	48	2.3	1.4-4.0	110	1.9	1.3-2.6
Other RT
No	3013	85	1 (ref)		14	1 (ref)
Yes	16	1	4.7	0.6-38.4	2	5.9	1.4-25.1
HSCT, TBI, etoposide^c (mutually exclusive groups)
No HSCT	2728	70	1 (ref)		171	1 (ref)	0.6–4.8
HSCT, no TBI with and without etoposide	83	3	3.8	1.1-13.8	4	1.7	0.6-4.8
HSCT, TBI, without etoposide	25	2	1.5	0.5-6.5	9	4.9	2.3-10.5
HSCT, TBI, with etoposide	159	11	5.7	2.5-12.8	29	6.3	3.8-10.3
Anthracyclines mg/m²
None	923	29	1 (ref)		83	1 (ref)
<200	1288	39	1.4	0.8-2.5	91	1.1	0.8-1.6
200+	752	17	1.5	0.7-3.2	35	1.0	0.6-1.6
Alkylating agents mg/m²
None	1021	40	1 (ref)		99	1 (ref)
<2000	1125	13	1.0	0.5-2.1	29	0.9	0.6-1.5
2000+	809	32	1.0	0.5-1.9	81	1.2	0.8-1.7

These analyses were done within a subset of the cohort for whom we had additional treatment details available (n = 3029)².
SMN Subsequent malignant neoplasm, SNMN Subsequent non-malignant neoplasm, CI Confidence interval, HR Hazard ratio, HSCT Hematopoietic stem cell transplantation, TBI Total body irradiation.
^a109 observations deleted due to missing information.
^b150 survivors were not included in the analysis due to missing data.
^cEtoposide as part of pre-treatment and conditioning regimen.

Quick links

Search